A treatment that has been used for more than two decades to
prevent thrombosis in pregnant women may not be as effective at preventing
pregnancy-related complications after all. A study of pregnant women at high
risk for developing thrombosis showed that low molecular weight heparin (LMWH)
may actually not be effective in preventing clotting disorders. Published by
The Lancet on July 24, the study was led by Marc Rodger, MD, Chief of
Hematology at The Ottawa Hospital.
The
authors of the editorial that accompanies the study point out that a
lack of clear guidelines, coupled with the desire to avoid poor
outcomes, could lead practitioners to treat despite the lack of
evidence. The editorial goes on to anticipate that the study results may
lead clinicians to discontinue using heparin in these patients but does
cite some problems with the study, including the small sample size, the
long length of time to recruit the participants, the lower-than
expected number of adverse events, and the confounding use of aspirin in
both groups. - See more at:
http://www.obgyn.net/use-heparin-pregnancy-may-have-no-benefit#sthash.mezHUk3h.dpuf
The authors of the editorial that accompanies the study
point out that a lack of clear guidelines, coupled with the desire to avoid
poor outcomes, could lead practitioners to treat despite the lack of evidence.
The editorial goes on to anticipate that the study results may lead clinicians
to discontinue using heparin in these patients but does cite some problems with
the study, including the small sample size, the long length of time to recruit
the participants, the lower-than expected number of adverse events, and the
confounding use of aspirin in both groups.
More at http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960793-5/abstract
A
treatment that has been used for more than two decades to prevent
thrombosis in pregnant women may not be as effective at preventing
pregnancy-related complications after all. A study of pregnant women at
high risk for developing thrombosis showed that low molecular weight
heparin (LMWH) may actually not be effective in preventing clotting
disorders. Published by The Lancet on July 24, the study was led by Marc
Rodger, MD, Chief of Hematology at The Ottawa Hospital. - See more at:
http://www.obgyn.net/use-heparin-pregnancy-may-have-no-benefit#sthash.mezHUk3h.dpuf
A
treatment that has been used for more than two decades to prevent
thrombosis in pregnant women may not be as effective at preventing
pregnancy-related complications after all. A study of pregnant women at
high risk for developing thrombosis showed that low molecular weight
heparin (LMWH) may actually not be effective in preventing clotting
disorders. Published by The Lancet on July 24, the study was led by Marc
Rodger, MD, Chief of Hematology at The Ottawa Hospital. - See more at:
http://www.obgyn.net/use-heparin-pregnancy-may-have-no-benefit#sthash.mezHUk3h.dpuf
A
treatment that has been used for more than two decades to prevent
thrombosis in pregnant women may not be as effective at preventing
pregnancy-related complications after all. A study of pregnant women at
high risk for developing thrombosis showed that low molecular weight
heparin (LMWH) may actually not be effective in preventing clotting
disorders. Published by The Lancet on July 24, the study was led by Marc
Rodger, MD, Chief of Hematology at The Ottawa Hospital. - See more at:
http://www.obgyn.net/use-heparin-pregnancy-may-have-no-benefit#sthash.mezHUk3h.dpuf
A
treatment that has been used for more than two decades to prevent
thrombosis in pregnant women may not be as effective at preventing
pregnancy-related complications after all. A study of pregnant women at
high risk for developing thrombosis showed that low molecular weight
heparin (LMWH) may actually not be effective in preventing clotting
disorders. Published by The Lancet on July 24, the study was led by Marc
Rodger, MD, Chief of Hematology at The Ottawa Hospital. - See more at:
http://www.obgyn.net/use-heparin-pregnancy-may-have-no-benefit#sthash.mezHUk3h.dpuf
